In 2005, Raymond V. Gilmartin earned $2.41M in total compensation at Merck & Co., including $1.60M salary and $800.00K bonus. Led Merck & Co. as CEO for 10 years.
Compensation History
Annual executive compensation data for Raymond V. Gilmartin, including salary, bonuses, and stock awards.
Year
2005
Total Compensation
$2.41M
Salary
$1.60M
Bonus
$800.00K
Other
$9.45K
Salary
$1.60MBoard Justification
The compensation philosophy of the company for the CEO in 2005 is to ensure that rewards are closely linked to Company-wide, division, area, team and individual performance, and to align the interests of the Company’s employees with those of its stockholders through potential stock ownership.
Bonus
$800.00KBoard Justification
The bonus award was determined in light of Company performance, as well as Mr. Gilmartin’s performance against his personal performance objectives, which were established by the Committee at the beginning of the performance year to support the achievement of the Company’s objectives.
Other Compensation
$9.45KBoard Justification
Company contribution to the Merck & Co., Inc. Employee Savings and Security Plan.
Restricted Stock
Board Justification
Mr. Gilmartin received stock options and PSUs, but the vested stock for 2005 is not specified in the provided text.
Performance Metrics
The performance metrics of the company for the CEO that determines the compensation in 2005 included earnings per share, sales revenue, and return on operating assets compared to business plan performance targets set at the beginning of the year.
Raymond V. Gilmartin
Ex-CEO of Merck & Co.
Education
MBA from Harvard Business School
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
March 1, 1941 - 84 years ago
CEO of Merck & Co. for
10 years 11 months (Jun 1994 - May 2005)
Previous Experience
CEO of Becton Dickinson
Other Merck & Co. CEOs
Holdings
Track Raymond V. Gilmartin's stock holdings and portfolio value over time.
Insider Trading
Raymond V. Gilmartin's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Raymond V. Gilmartin with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Joseph K. Belanoff, M.D.
Founder and CEO of Corcept Therapeutics
2023 Compensation
Stock
$0.00
Salary
$1.10M
Bonus
$1.32M
Other
$22.50K
Total Holdings
$21.20M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M